Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1 study found for:    NCT01326871
Show Display Options
Rank Status Study
1 Active, not recruiting A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer
Conditions: Transitional Cell Carcinoma of Bladder;   Urethra Cancer;   Ureter Cancer;   Malignant Tumor of Renal Pelvis
Interventions: Drug: Cisplatin;   Drug: Gemcitabine;   Biological: ALT-801

Study has passed its completion date and status has not been verified in more than two years.